Rockaway Hd Llc is a medicare approved dialysis facility center in Far Rockaway, New York and it has 16 dialysis stations. It is located in Queens county at 529 Beach 20th Street, Far Rockaway, NY, 11691. You can reach out to the office of Rockaway Hd Llc at (718) 327-4503. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Rockaway Hd Llc has the following ownership type - Profit. It was first certified by medicare in March, 2013. The medicare id for this facility is 332694 and it accepts patients under medicare ESRD program.
| Name | Rockaway Hd Llc |
|---|---|
| Location | 529 Beach 20th Street, Far Rockaway, New York |
| No. of Dialysis Stations | 16 |
| Medicare ID | 332694 |
| Managed By | Independent |
| Ownership Type | Profit |
| Late Shifts | No |
| 529 Beach 20th Street, Far Rockaway, New York, 11691 | |
| (718) 327-4503 | |
News Archive
Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.
Humana Inc. today announced that the company will cover the administration cost of the H1N1 (swine flu) vaccine for all fully insured members including those members who have a benefit plan that excludes immunization coverage. All co-payment, coinsurance and deductibles will be waived for the administration of the H1N1 vaccination regardless of the preventative-services benefit currently provided in these members' plans.
› Verified 6 days ago
| NPI Number | 1194085662 |
| Organization Name | Rockaway Dialysis |
| Doing Business As | Rockaway Hd Llc |
| Address | 529 Beach 20th St Far Rockaway, New York, 11691 |
| Phone Number | (718) 327-7307 |
News Archive
Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.
Humana Inc. today announced that the company will cover the administration cost of the H1N1 (swine flu) vaccine for all fully insured members including those members who have a benefit plan that excludes immunization coverage. All co-payment, coinsurance and deductibles will be waived for the administration of the H1N1 vaccination regardless of the preventative-services benefit currently provided in these members' plans.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 37 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 30 |
News Archive
Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.
Humana Inc. today announced that the company will cover the administration cost of the H1N1 (swine flu) vaccine for all fully insured members including those members who have a benefit plan that excludes immunization coverage. All co-payment, coinsurance and deductibles will be waived for the administration of the H1N1 vaccination regardless of the preventative-services benefit currently provided in these members' plans.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 90 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 667 |
| Percentage of adult patients getting regular hemodialysis at the center | 76 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.
Humana Inc. today announced that the company will cover the administration cost of the H1N1 (swine flu) vaccine for all fully insured members including those members who have a benefit plan that excludes immunization coverage. All co-payment, coinsurance and deductibles will be waived for the administration of the H1N1 vaccination regardless of the preventative-services benefit currently provided in these members' plans.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Rockaway Hd Llc with elevated calcium levels.
| Patients with hypercalcemia | 92 |
| Hypercalcemia patient months | 701 |
| Patients with Serumphosphor | 84 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 26 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 31 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.
Humana Inc. today announced that the company will cover the administration cost of the H1N1 (swine flu) vaccine for all fully insured members including those members who have a benefit plan that excludes immunization coverage. All co-payment, coinsurance and deductibles will be waived for the administration of the H1N1 vaccination regardless of the preventative-services benefit currently provided in these members' plans.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 53 |
| Patient months included in arterial venous fistula and catheter summaries | 392 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 69 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 17 |
News Archive
Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.
Humana Inc. today announced that the company will cover the administration cost of the H1N1 (swine flu) vaccine for all fully insured members including those members who have a benefit plan that excludes immunization coverage. All co-payment, coinsurance and deductibles will be waived for the administration of the H1N1 vaccination regardless of the preventative-services benefit currently provided in these members' plans.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 55 |
| Hospitalization Rate in facility | 202 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 336.3 |
| Hospitalization Rate: Lower Confidence Limit | 125.7 |
News Archive
Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.
Humana Inc. today announced that the company will cover the administration cost of the H1N1 (swine flu) vaccine for all fully insured members including those members who have a benefit plan that excludes immunization coverage. All co-payment, coinsurance and deductibles will be waived for the administration of the H1N1 vaccination regardless of the preventative-services benefit currently provided in these members' plans.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at Rockaway Hd Llc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 23.3 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.2 |
| Readmission Rate: Lower Confidence Limit | 12.9 |
News Archive
Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.
A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine
Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.
Humana Inc. today announced that the company will cover the administration cost of the H1N1 (swine flu) vaccine for all fully insured members including those members who have a benefit plan that excludes immunization coverage. All co-payment, coinsurance and deductibles will be waived for the administration of the H1N1 vaccination regardless of the preventative-services benefit currently provided in these members' plans.
› Verified 6 days ago